Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
24.80
-0.15 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 31.9, with a low estimate of 16 and a high estimate of 49. The average target predicts an increase of 28.63% from the current stock price of 24.80.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 1 | 2 | 2 |
| Hold | 2 | 2 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $37 → $41 | Buy | Maintains | $37 → $41 | +65.32% | Apr 2, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $44 → $45 | Strong Buy | Maintains | $44 → $45 | +81.45% | Mar 5, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $36 → $49 | Buy | Maintains | $36 → $49 | +97.58% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +29.03% | Mar 2, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $30 → $23 | Buy → Hold | Downgrades | $30 → $23 | -7.26% | Feb 12, 2026 |
Financial Forecast
Revenue This Year
94.12M
from 247.00M
Decreased by -61.89%
Revenue Next Year
137.06M
from 94.12M
Increased by 45.62%
EPS This Year
-4.02
from -3.29
EPS Next Year
-3.41
from -4.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 231.0M | 372.2M | ||||||
| Avg | 94.1M | 137.1M | ||||||
| Low | 6.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.5% | 295.4% | ||||||
| Avg | -61.9% | 45.6% | ||||||
| Low | -97.2% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.13 | -2.14 | ||||||
| Avg | -4.02 | -3.41 | ||||||
| Low | -5.10 | -3.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.